The Global Transplant Diagnostics Market size was estimated at USD 3.9 billion in 2021 and is expected to hit around USD 7.9 billion by 2031, poised to grow at a compound annual growth rate (CAGR) of 6.7% from 2022 to 2031.
Global Transplant Diagnostics Market: Breakup by Region, (USD Billion) 2022 & 2031
Source: Primary Research and Secondary Research Analysis
The industry as a whole that supplies diagnostic equipment and services necessary for organ and tissue transplant operations across the globe is referred to as the global transplant diagnostics market. By enabling compatibility testing, identifying potential dangers, and improving overall transplant management, this market is essential to guaranteeing optimal transplant outcomes. It includes a broad range of goods and services, such as histocompatibility testing, genomics and molecular diagnostics, and other specialised tests intended to evaluate donor-recipient compatibility.
The growing number of transplant procedures performed worldwide, together with the rising frequency of chronic diseases that result in organ failure, are the main factors driving the market's expansion. Technological developments like next-generation sequencing and molecular testing techniques support the ongoing development of transplant diagnostics by allowing for more accurate and individualised evaluations. Additionally, the growing recognition among medical professionals of the significance of precise and timely diagnostic testing in transplant procedures drives market expansion.
Notable trends are reshaping the landscape of the global transplant diagnostics market. First, thanks to developments in genomics and molecular testing, there is an increasing focus on precision medicine and customised diagnoses. Transplant success rates are rising as a result of this trend's improved capacity to match donors and recipients. Furthermore, there is a growing trend towards the integration of artificial intelligence (AI) and machine learning in transplant diagnostics. This approach offers improved capabilities for data analysis and predictive modelling, which may be utilised to optimise organ matching and post-transplant monitoring.
The growing use of non-invasive diagnostic methods, including liquid biopsy and circulating cell-free DNA analysis, which lessen the need for invasive procedures and give doctors real-time information about the health of the transplant, is another noteworthy trend. The need for comprehensive diagnostic solutions is being driven by the growing recognition of the need for early detection and management of problems connected to transplantation.
Additionally, there is a rise in joint ventures involving biotechnology firms, diagnostic labs, and healthcare facilities in the global transplant diagnostics market. These partnerships seek to serve the changing requirements of the transplant community, promote innovation, and advance research and development. These trends, taken together, point to a dynamic and forward-thinking transplant diagnostics market, marked by technological advancements, increased collaboration, and a focus on personalised, non-invasive diagnostic solutions to improve patient outcomes as the demand for organ transplants rises globally.
Recent Developments:
The global transplant diagnostics market has seen a number of significant advancements in recent years that demonstrate the industry's dedication to developing diagnostic technologies and enhancing transplant outcomes. A notable advancement is the combination of sequencing and cutting-edge genomics technology to provide more accurate compatibility evaluations. Next-generation sequencing (NGS) has made it possible to analyse genetic markers more thoroughly, which has improved donor-recipient matching and decreased the chance of graft rejection in transplant diagnostics.
In addition, there has been a notable upsurge in the creation and implementation of innovative biomarkers and assays that provide enhanced sensitivity and specificity in identifying indications of rejection and malfunction in transplants. With improved monitoring of transplant recipients, early intervention and individualised treatment plans will be possible.
Table of Content
Global Transplant Diagnostics Market Research Report, 2020-2031.
Chapter 1. Introduction
1.1. Report description
1.2. Key market segments
1.3. Regional Scope
1.4. Executive Summary
Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Secondary Analyst Tools and Models
Chapter 3. Market Dynamics
3.1. Market driver analysis
3.2. Market restraint analysis
3.3. Market Opportunity
3.4. Market Challenges
3.5. Impact analysis of COVID-19 on the Transplant Diagnostics Market
Chapter 4. Market Variables and Outlook
4.1. SWOT Analysis
4.1.1. Strengths
4.1.2. Weaknesses
4.1.3. Opportunities
4.1.4. Threats
4.2. Supply Chain Analysis
4.3. PESTEL Analysis
4.3.1. Political Landscape
4.3.2. Economic Landscape
4.3.3. Social Landscape
4.3.4. Technological Landscape
4.3.5. Environmental Landscape
4.3.6. Legal Landscape
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitute
4.4.4. Threat of New Entrant
4.4.5. Competitive Rivalry
Chapter 5. Transplant Diagnostics Market: Product Type Estimates & Trend Analysis
5.1. Transplant Diagnostics Market value share and forecast, (USD Billion) (2020 to 2031)
5.2. Incremental Growth Analysis and Infographic Presentation
5.3. Reagents And Consumables
5.3.1. Market Size & Forecast, (USD Billion) 2020-2031
5.4. Instruments
5.4.1. Market Size & Forecast, (USD Billion) 2020-2031
5.5. Software
5.5.1. Market Size & Forecast, (USD Billion) 2020-2031
5.6. Services
5.6.1. Market Size & Forecast, (USD Billion) 2020-2031
Chapter 6. Transplant Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Transplant Diagnostics Market value share and forecast, (USD Billion) (2020 to 2031)
6.2. Incremental Growth Analysis and Infographic Presentation
6.3. Molecular Assays
6.3.1. Market Size & Forecast, (USD Billion) 2020-2031
6.4. Serological Assays
6.4.1. Market Size & Forecast, (USD Billion) 2020-2031
6.5. Next-Generation Sequencing
6.5.1. Market Size & Forecast, (USD Billion) 2020-2031
Chapter 7. Transplant Diagnostics Market: Transplant Type Size Estimates & Trend
Analysis
7.1. Transplant Diagnostics Market value share and forecast, (USD Billion) (2020 to 2031)
7.2. Incremental Growth Analysis and Infographic Presentation
7.3. Kidney
7.3.1. Market Size & Forecast, (USD Billion) 2020-2031
7.4. Liver
7.4.1. Market Size & Forecast, (USD Billion) 2020-2031
7.5. Heart
7.5.1. Market Size & Forecast, (USD Billion) 2020-2031
7.6. Lung
7.6.1. Market Size & Forecast, (USD Billion) 2020-2031
7.7. Others
7.7.1. Market Size & Forecast, (USD Billion) 2020-2031
Chapter 8. Transplant Diagnostics Market: Application Estimates & Trend Analysis
8.1. Transplant Diagnostics Market value share and forecast, (USD Billion) (2020 to 2031)
8.2. Incremental Growth Analysis and Infographic Presentation
8.3. Pre-Transplant Screening
8.3.1. Market Size & Forecast, (USD Billion) 2020-2031
8.4. Post-Transplant Monitoring
8.4.1. Market Size & Forecast, (USD Billion) 2020-2031
8.5. Research Applications
8.5.1. Market Size & Forecast, (USD Billion) 2020-2031
Chapter 9. Transplant Diagnostics Market: Regional Estimates & Trend Analysis
9.1. Transplant Diagnostics Market value share and forecast, (USD Billion) (2020 to 2031)
9.2. Incremental Growth Analysis and Infographic Presentation
9.3. North America
9.3.1. Market Size & Forecast, (USD Billion) 2020-2031
9.4. Europe
9.4.1. Market Size & Forecast, (USD Billion) 2020-2031
9.5. Asia Pacific
9.5.1. Market Size & Forecast, (USD Billion) 2020-2031
9.6. Middle East & Africa
9.6.1. Market Size & Forecast, (USD Billion) 2020-2031
9.7. Latin America
9.7.1. Market Size & Forecast, (USD Billion) 2020-2031
Chapter 10. Transplant Diagnostics Market: Country Estimates & Trend Analysis
10.1. Transplant Diagnostics Market value share and forecast, (USD Billion) (2020 to
2031)
10.2. Incremental Growth Analysis and Infographic Presentation
10.3. U.S.
10.3.1. Market Size & Forecast, (USD Billion) 2020-2031
10.4. Canada
10.4.1. Market Size & Forecast, (USD Billion) 2020-2031
10.5. Mexico
10.5.1. Market Size & Forecast, (USD Billion) 2020-2031
10.6. UK
10.6.1. Market Size & Forecast, (USD Billion) 2020-2031
10.7. France
10.7.1. Market Size & Forecast, (USD Billion) 2020-2031
10.8. Germany
10.8.1. Market Size & Forecast, (USD Billion) 2020-2031
10.9. Russia
10.9.1. Market Size & Forecast, (USD Billion) 2020-2031
10.10. Italy
10.10.1. Market Size & Forecast, (USD Billion) 2020-2031
10.11. Spain
10.11.1. Market Size & Forecast, (USD Billion) 2020-2031
10.12. China
10.12.1. Market Size & Forecast, (USD Billion) 2020-2031
10.13. India
10.13.1. Market Size & Forecast, (USD Billion) 2020-2031
10.14. Japan
10.14.1. Market Size & Forecast, (USD Billion) 2020-2031
10.15. Indonesia
10.15.1. Market Size & Forecast, (USD Billion) 2020-2031
10.16. South Korea
10.16.1. Market Size & Forecast, (USD Billion) 2020-2031
10.17. Australia
10.17.1. Market Size & Forecast, (USD Billion) 2020-2031
10.18. Brazil
10.18.1. Market Size & Forecast, (USD Billion) 2020-2031
10.19. Argentina
10.19.1. Market Size & Forecast, (USD Billion) 2020-2031
10.20. Saudi Arabia
10.20.1. Market Size & Forecast, (USD Billion) 2020-2031
10.21. UAE
10.21.1. Market Size & Forecast, (USD Billion) 2020-2031
10.22. South Africa
10.22.1. Market Size & Forecast, (USD Billion) 2020-2031
Chapter 11. Competitive Landscape
11.1. Company Market Share Analysis
11.2. Vendor Landscape
11.3. Competition Dashboard
Chapter 12. Company Profiles
12.1. Business Overview, Product Landscape, Financial Performanceand Company
Strategies for below companies
12.2. Thermo Fisher Scientific
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Benchmarking
12.2.4. Geographic Footprint
12.2.5. Strategic Initiatives
12.3. Qiagen N.V.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Benchmarking
12.3.4. Geographic Footprint
12.3.5. Strategic Initiatives
12.4. Illumina, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Benchmarking
12.4.4. Geographic Footprint
12.4.5. Strategic Initiatives
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Benchmarking
12.5.4. Geographic Footprint
12.5.5. Strategic Initiatives
12.6. Bio-Rad Laboratories, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Benchmarking
12.6.4. Geographic Footprint
12.6.5. Strategic Initiatives
12.7. Immucor, Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Benchmarking
12.7.4. Geographic Footprint
12.7.5. Strategic Initiatives
12.8. CareDx, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Benchmarking
12.8.4. Geographic Footprint
12.8.5. Strategic Initiatives
12.9. Becton, Dickinson and Company
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Benchmarking
12.9.4. Geographic Footprint
12.9.5. Strategic Initiatives
12.10. Luminex Corporation
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Benchmarking
12.10.4. Geographic Footprint
12.10.5. Strategic Initiatives
12.11. Abbott Laboratories
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Benchmarking
12.11.4. Geographic Footprint
12.11.5. Strategic Initiatives
12.12. Grifols, S.A.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Benchmarking
12.12.4. Geographic Footprint
12.12.5. Strategic Initiatives
12.13. Beckman Coulter, Inc.
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Benchmarking
12.13.4. Geographic Footprint
12.13.5. Strategic Initiatives
12.14. Bio-Techne Corporation
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Benchmarking
12.14.4. Geographic Footprint
12.14.5. Strategic Initiatives
12.15. Hologic, Inc.
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Product Benchmarking
12.15.4. Geographic Footprint
12.15.5. Strategic Initiatives
12.16. Olerup International AB
12.16.1. Company Overview
12.16.2. Financial Performance
12.16.3. Product Benchmarking
12.16.4. Geographic Footprint
12.16.5. Strategic Initiatives
Chapter 13. Conclusion
Our reports with in-depth insights will equip you to succeed in your business plans.
Get instant access to the information you need to make the right decision.
Explore where opportunities lie for you and mitigate the risks.
We are one of the most trusted brands setting benchmarks of excellence.
